Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | PRNP | P04156 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | NQO2 | P16083 | 7/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NQO1 | P15559 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29769759 | 0.79 | S1PR4 (0.43) | KDM4EL3MBTL1ALDH1A1MAPTNQO2 | |
| SCHEMBL4977234 | 0.79 | KDM4E (0.52) | KDM4EL3MBTL1ALDH1A1MAPTNQO2 | |
| SCHEMBL12093603 | 0.79 | KDM4E (0.52) | KDM4EL3MBTL1ALDH1A1MAPTPRNP | |
| SCHEMBL2144116 | 0.79 | S1PR4 (0.43) | KDM4EL3MBTL1ALDH1A1MAPTNQO2 | |
| SCHEMBL30082515 | 0.78 | S1PR4 (0.34) | KDM4EL3MBTL1ALDH1A1MAPTPRNP | |
| SCHEMBL16742675 | 0.78 | S1PR4 (0.34) | KDM4EL3MBTL1ALDH1A1MAPTPRNP | |
| SCHEMBL14971502 | 0.77 | NQO2 (0.40) | KDM4EL3MBTL1ALDH1A1MAPTNQO2 | |
| SCHEMBL11894304 | 0.77 | GRM5 (0.36) | ALDH1A1MAPTACHE | |
| SCHEMBL6513147 | 0.77 | ADORA2A (0.49) | KDM4EL3MBTL1ALDH1A1MAPTMEN1 | |
| SCHEMBL29364421 | 0.77 | TSHR (0.44) | KDM4EL3MBTL1ALDH1A1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138991-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4705298-A2 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | Moma Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12559508-B2 | Semi-saturated bicyclic derivatives and related uses | MOMA THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| EP-4658656-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | Beone Medicines I GmbH (CH) | 2025-12-10 | — | — | EP | disclosed |
| US-20250346597-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | BEONE MEDICINES I GMBH (CH) | 2025-11-13 | — | — | US | disclosed |
| US-12448368-B2 | Indole compounds as androgen receptor modulators | NIDO BIOSCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20250230171-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS, INC. | 2025-07-17 | — | — | US | disclosed |
| US-20250122176-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES INC (US) | 2025-04-17 | — | — | US | disclosed |
| US-20250092021-A9 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES, INC. | 2025-03-20 | — | — | US | disclosed |
| WO-2024211836-A2 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS, INC. (US) | 2024-10-10 | — | — | WO | disclosed |
| US-20150080412-A1 | TRIAZOLONE COMPOUNDS AND USES THEREOF | INCEPTION 2, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| EP-2822931-A1 | TRIAZOLONE COMPOUNDS AND USES THEREOF | Inception 2, Inc. (US) | 2015-01-14 | — | — | EP | disclosed |
| US-20140309220-A1 | BENZOXAZINES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-10-16 | — | — | US | disclosed |
| US-20140309220-A1 | BENZOXAZINES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-10-16 | — | — | US | disclosed |
| US-20140309220-A1 | BENZOXAZINES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-10-16 | — | — | US | disclosed |
| WO-2013134562-A1 | TRIAZOLONE COMPOUNDS AND USES THEREOF | INCEPTION 2, INC. (US) | 2013-09-12 | — | — | WO | disclosed |
| WO-2013067248-A1 | BENZOXAZINES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013067248-A1 | BENZOXAZINES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-10 | — | — | WO | disclosed |
| WO-2009001127-A1 | CYANOCYCLOPROPYLCARBOXAMIDES AS CATHEPSIN INHIBITORS | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | WO | disclosed |
| WO-2009001127-A1 | CYANOCYCLOPROPYLCARBOXAMIDES AS CATHEPSIN INHIBITORS | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250230171-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | POLQ, POLB, POLK | KDM4E 2459/4885L3MBTL1 3878/4885ALDH1A1 1052/4885 |
| US-20260138991-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | POLA1, SUB1, CTDSP1 | KDM4E 4515/4885L3MBTL1 1344/4885ALDH1A1 840/4885 |
| US-20250122176-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, NR5A1 | KDM4E 1654/4885L3MBTL1 3975/4885ALDH1A1 2325/4885 |
| US-20150080412-A1 | TRIAZOLONE COMPOUNDS AND USES THEREOF | PPARA, PPARG, PPARD | KDM4E 2341/4885L3MBTL1 3624/4885ALDH1A1 673/4885 |
| US-12559508-B2 | Semi-saturated bicyclic derivatives and related uses | POLA1, CTDSP1, SUB1 | KDM4E 4522/4885L3MBTL1 1625/4885ALDH1A1 589/4885 |
| US-20250346597-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | DGKG, DGKA, DGKK | KDM4E 2066/4885L3MBTL1 4317/4885ALDH1A1 4075/4885 |
| US-20250092021-A9 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, NR5A1 | KDM4E 1654/4885L3MBTL1 3975/4885ALDH1A1 2325/4885 |
| US-12448368-B2 | Indole compounds as androgen receptor modulators | AR, FSHR, ADRB3 | KDM4E 1533/4885L3MBTL1 3847/4885ALDH1A1 2697/4885 |
| US-20140309220-A1 | BENZOXAZINES AS MODULATORS OF ION CHANNELS | KCNJ1, KCNJ2, KCNJ11 | KDM4E 1795/4885L3MBTL1 4347/4885ALDH1A1 1441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.